Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells

Roelle, Susanne; Grosse, Robert; Buech, Thomas; Chubanov, Vladimir; Gudermann, Thomas

doi:10.1038/sj.onc.1210819

Cited by 52 publications

(53 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, downregulation of Pyk2 expression by RNAi attenuated Ang II-induced Src activation, while pharmacological inhibition of the Src family resulted in decreased Pyk2 activation. Roellle et al reported similar findings in the signaling mechanism initiated by another Gq/11-coupled receptor for neuropeptides (35). It is suggested that Pyk2 and Src depend on each other for their full activation, and the two tyrosine kinases may not be placed in a sequential order (36,37).…”

Section: Discussionsupporting

confidence: 56%

Angiotensin II-Induced Osteopontin Expression in Vascular Smooth Muscle Cells Involves Gq/11, Ras, ERK, Src and Ets-1

et al. 2008

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 56%

Angiotensin II-Induced Osteopontin Expression in Vascular Smooth Muscle Cells Involves Gq/11, Ras, ERK, Src and Ets-1

et al. 2008

View full text Add to dashboard Cite

“…Silencing was in fact potent (80% of protein knockdown, approximately) and heterogeneous ( Figure 2B and C). This result correlates with the reduced fraction of successfully targeted cells, as assessed in the present study with FITC-labeled nucleic acid, and in agreement with the low transfection efficiencies previously reported for SCLC cell lines (17,18). It is important to note that, in a previous report, transfection of SW2 cells with anti-survivin siRNA associated with oligofectamine led to the same level of protein down-regulation (50%) (19).…”

Section: Discussionsupporting

confidence: 77%

In vitro modulation of Bcl-2 levels in small cell lung cancer cells: effects on cell viability

Santos

Pereira

Lima

et al. 2010

Braz J Med Biol Res

View full text Add to dashboard Cite

“…They include c-Kit, IGF-IR and c-Src (21,25). Among them, only c-Src was more activated in N417 cells compared with H209 cells.…”

Section: Discussionmentioning

confidence: 99%

“…In previous studies, it has been proposed that the autocrine loop performs an important function in the proliferation of SCLC cells (21). c-Kit, IGF-IR and c-Src are reported as tyrosine kinases that participate in the autocrine loop of SCLC cells (21).…”

Section: Effect Of C-src Inhibitor On Akt Activity and Drug Interactimentioning

confidence: 99%

“…c-Kit, IGF-IR and c-Src are reported as tyrosine kinases that participate in the autocrine loop of SCLC cells (21). To seek what tyrosine kinase is activated in N417 cells, we evaluated the expression or the activation states of IGF-IR, c-Kit and c-Src by Western blot analysis, comparing the results with those in H209 cells.…”

Section: Effect Of C-src Inhibitor On Akt Activity and Drug Interactimentioning

confidence: 99%

See 1 more Smart Citation

Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: Implication of c-Src and its inhibitor

Ueda

Igishi²,

Hashimoto³

et al. 2009

Int J Oncol

View full text Add to dashboard Cite

Abstract. Small cell lung cancer (SCLC) is one of the intractable malignancies. The goal of this study was to clarify whether Akt activity is involved with chemo-resistance and to improve the sensitivity of SCLC cells to the current standard chemotherapeutic drugs with agents that are expected to suppress Akt activity through tyrosine kinase inhibition. Although Akt activity seemed to be involved with the sensitivity of SCLC cells to chemotherapeutic agents (cisplatin, etoposide, SN38 and amrubicin), in Akt-activated N417 cells, only amrubicin exerted synergistic cell growth inhibition when combined with an Akt inhibitor, LY294002. A non-specific tyrosine kinase inhibitor, genistein, suppressed Akt and showed synergistic interaction in combination with amrubicin in N417 cells. Among tyrosine kinases (insulin-like growth factor I receptor, c-Kit and c-Src), only c-Src was activated in N417 cells compared with Akt-inactive H209 cells. A c-Srcspecific inhibitor, PP2, and a clinically available multi-tyrosine kinase inhibitor, dasatinib, suppressed Akt activity in parallel with c-Src inhibition. Both PP2 and dasatinib exerted synergistic growth inhibition of N417 cells in the combination with amrubicin. In immunohistochemical analysis, c-Src was expressed in 17 of 19 of the SCLC tumor tissues. These observations suggested that Akt suppression enhances the cytotoxicity of amrubicin, and for the purpose of Akt suppression, c-Src is a promising target in SCLC.

show abstract

Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells

Cited by 52 publications

References 32 publications

Angiotensin II-Induced Osteopontin Expression in Vascular Smooth Muscle Cells Involves Gq/11, Ras, ERK, Src and Ets-1

Angiotensin II-Induced Osteopontin Expression in Vascular Smooth Muscle Cells Involves Gq/11, Ras, ERK, Src and Ets-1

In vitro modulation of Bcl-2 levels in small cell lung cancer cells: effects on cell viability

Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: Implication of c-Src and its inhibitor

Contact Info

Product

Resources

About